Related Experiment Video
Updated: Jun 3, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
Published on: June 4, 2012
Emerging infectious endocarditis due to Scedosporium prolificans: a model of therapeutic complexity
M L Fernandez Guerrero1, E Askari, E Prieto
1Division of Infectious Diseases and Haematology (Department of Medicine), Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Spain, Aveda. Reyes Católicos 2, 28040 Madrid, Spain. mlfernandez@fjd.es
Abstract:
Scedosporium prolificans is an emerging agent for severe infections. Although among the dematiaceous fungi Scedosporium is the most frequently isolated in blood cultures, Scedosporium endocarditis is rarely reported. We show herein a patient with acute leukaemia who developed S. prolificans endocarditis. Twelve cases were found in an extensive review of the English literature. In six cases (46%), there was predisposing heart conditions such as a prosthetic valve or an intracavitary device. Only 4 patients (31%) were immunocompromised hosts with haematologic neoplasia, solid-organ transplantation or acquired immunodeficiency syndrome (AIDS). Exposure to Scedosporium was observed in immunocompetent patients who developed infection while in the community. Scedosporium endocarditis occurred on both sides of the heart. Systemic and pulmonary emboli and other metastatic complications were seen in all of these patients. The overall mortality was 77% and, specifically, all of the immunocompromised hosts and 6 out of 7 patients with mitral or aortic valve endocarditis died. Patients with right-sided endocarditis associated with a removable intracardiac device exhibited a better prognosis. Scedosporium endocarditis, although still rare, is an emerging infection with an ominous prognosis. At the present time, valve replacement or the removal of cardiac devices plus combined antifungal treatment may offer the best possibility of cure.
Insights
Scedosporium prolificans causes severe infections, rarely endocarditis. This emerging fungal infection has a high mortality rate, especially in immunocompromised patients, but treatment involving surgery and antifungals may improve outcomes.
Area of Science:
- Mycology
- Infectious Diseases
- Cardiology
Background:
- Scedosporium prolificans is an emerging fungal pathogen causing severe infections.
- While frequently isolated in blood cultures, Scedosporium endocarditis remains a rare clinical entity.
Observation:
- This study presents a case of Scedosporium prolificans endocarditis in a patient with acute leukemia.
- A literature review identified 12 cases, revealing predisposing cardiac conditions in 46% and immunocompromised status in 31% of patients.
- Infections occurred in both immunocompromised and immunocompetent individuals, with systemic and pulmonary emboli being common complications.
Findings:
- Scedosporium endocarditis is associated with a high overall mortality of 77%.
- Mortality was particularly high in immunocompromised hosts and patients with left-sided (mitral/aortic) valve endocarditis.
- Right-sided endocarditis with removable cardiac devices showed a better prognosis.
Implications:
- Scedosporium endocarditis, though rare, is an emerging infection with a grave prognosis.
- Combined antifungal therapy and surgical intervention (valve replacement or device removal) represent the most promising treatment strategy.
- Increased awareness and prompt management are crucial for improving patient outcomes.
Related Concept Videos
Endocarditis III: Medical Management
Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis I: Introduction
Endocarditis IV: Nursing Management
Clinical Significance of Antibiotic Resistance
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies. Common...